CareSource considers Nulibry (fosdenopterin) not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.

DATE	ACTION/DESCRIPTION
6/24/2021	New policy for Nulibry (fosdenopterin) created.
04/28/2023	Added reference. Added more examples of presenting characteristics and clarified criterion. Added requirement for weight documentation.

References:

1. Nulibry (fosdenopterin) [package insert]. Charleston SC; Alcami Carolinas Corporation;2022.
2. Molybdenum cofactor deficiency. Genetics Home Reference. Accessed June 24, 2021. https://medlineplus.gov/genetics/condition/molybdenum-cofactor-deficiency/
3. Study of [illegible] (Formerly [illegible]) in Subjects with Molybdenum Cofactor Deficiency (MOCD) Type A. Clinica(t)-29(])29(])29(])29(])29(])290 612 792 re